Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,403,695.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $568.81, for a total value of $5,403,695.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at $23,044,199.53. This represents a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Stock Up 0.0%

Shares of UTHR stock opened at $571.35 on Friday. The firm has a market capitalization of $25.04 billion, a P/E ratio of 20.48, a P/E/G ratio of 1.62 and a beta of 0.75. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The stock’s fifty day simple moving average is $543.83 and its 200 day simple moving average is $497.42.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.19 EPS. As a group, equities research analysts expect that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on UTHR. HC Wainwright lifted their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. TD Cowen increased their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Raymond James Financial started coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Morgan Stanley boosted their price target on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Finally, Wells Fargo & Company upped their price objective on shares of United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Ten equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Torren Management LLC bought a new position in shares of United Therapeutics during the 4th quarter worth about $26,000. Activest Wealth Management boosted its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC bought a new position in shares of United Therapeutics during the 4th quarter worth about $31,000. Wilmington Savings Fund Society FSB boosted its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in shares of United Therapeutics during the 4th quarter worth about $48,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.